Brain tumor gene mapping project launches in Seattle

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 12
Volume 18
Issue 12

The Ivy Glioblastoma Atlas Project will track genetic mutations in glioblastoma multiforme and produce a free, online medical atlas. The Seattle-based project is a partnership between the Ben and Catherine Ivy Foundation, the Allen Institute for Brain Science, and the Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment at the Swedish Neuroscience Institute.

The Ivy Glioblastoma Atlas Project will track genetic mutations in glioblastoma multiforme and produce a free, online medical atlas. The Seattle-based project is a partnership between the Ben and Catherine Ivy Foundation, the Allen Institute for Brain Science, and the Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment at the Swedish Neuroscience Institute.

Research on the Glioblastoma Atlas Project (GAP) is slated for completion in 2013. The resulting atlas information will then be made available online for free use by the global medical and scientific communities.

GAP will target 1,000 genes, which were selected for study by a panel of physician scientists and medical professionals led by Greg Foltz, MD, co-director of the Ivy Center for Advanced Brain Tumor Treatment. Dr. Foltz will serve as the lead investigator on the atlas.

Articles in this issue
Cetuximab plus chemo boosts surgery in advanced colon ca
OB/GYN revises suggested age for cervical ca screening
Brain tumor gene mapping project launches in Seattle
PET timing guides radiation RX in lung ca
Experts take umbrage with federal panel change to age for mammo screening
Radiosurgery gains role for noncancer applications
New radiotracer shows early treatment response for patients with lung cancer
Addition of rituximab improves OS in chronic lymphocytic leukemia
Micromet scores multiple development deals
New agents for lymphoma take center stage
Vaccines plus screening could end cervical ca
Post-treatment pain remains clinically significant in breast cancer patients
Oncology dodges CMS worst case scenario
RCC adverse effects and symptoms: Kidney cancer specialists must meet new challenges
Classic phase II trials: Unable to meet the challenges in oncology, or an integral aspect of drug development?
Recent Videos
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Results showed no “deleterious reactions” with chlorotoxin-directed cellular therapy in a small cohort of patients with recurrent glioblastoma.
A novel CAR T-cell therapy may bind with more avidity, rather than affinity, to glioblastoma cells, said Michael Barish, PhD.
Using chlorotoxin as a targeting element may bind to more glioblastoma cells than other targeting entities, according to Michael Barish, PhD.
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Related Content
Data from a phase 1 trial demonstrate the safety and feasibility of administering chlorotoxin-based cellular therapy to those with recurrent glioblastoma.

Scorpion Venom Approach May Prove “Powerful” in Glioblastoma Research

Russ Conroy
November 13th 2025
Article

Data from a phase 1 trial demonstrate the safety and feasibility of administering chlorotoxin-based cellular therapy to those with recurrent glioblastoma.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Interim data from the phase 1b CLOVER-2 trial evaluating iopofosine I 131 in children and adults with high-grade glioma supported the FDA’s decision.

FDA Grants Iopofosine I 131 Rare Pediatric Drug Designation in R/R Glioma

Roman Fabbricatore
October 30th 2025
Article

Interim data from the phase 1b CLOVER-2 trial evaluating iopofosine I 131 in children and adults with high-grade glioma supported the FDA’s decision.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

Shwetal Mehta, PhD
January 27th 2025
Podcast

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Data from the phase 3 ROADS trial show significant gains in efficacy without increases in safety concerns following the use of GammaTile.

Collagen Implant May Improve Local Control of Metastatic Brain Tumors

Russ Conroy
October 23rd 2025
Article

Data from the phase 3 ROADS trial show significant gains in efficacy without increases in safety concerns following the use of GammaTile.

Molecular Characterization of a Rare Glioblastoma Case With Atypical Histopathologic Features

Molecular Characterization of a Rare Glioblastoma Case With Atypical Histopathologic Features

Nanuli Gvazava, MD;Tolga Tuncer, MD;Wei Zhang, MD, PhD;Anup Kasi, MD, MPH;Uma Bhoot
September 17th 2025
Article

A patient case of a 76-year-old man with a rare glioblastoma variant showcased the importance of molecular profiling in diagnosing and guiding treatment for brain tumors.